Published in Cholesterol on September 06, 2012
Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol (2014) 0.86
Lipoprotein(a) in cardiovascular diseases. Biomed Res Int (2012) 0.83
Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int J Biochem Cell Biol (2013) 0.78
Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study. J Diabetes Res (2013) 0.76
Production of human apolipoprotein(a) transgenic NIBS miniature pigs by somatic cell nuclear transfer. Exp Anim (2015) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Rho GTPases in cell biology. Nature (2002) 22.81
Platelet activation and atherothrombosis. N Engl J Med (2007) 6.18
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol (1990) 3.81
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM. Acta Pathol Microbiol Scand (1963) 3.13
Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation (1999) 3.08
Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol (2004) 3.03
Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science (1986) 2.67
Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation (1986) 2.06
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res (2008) 1.79
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol (1988) 1.73
Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol (2008) 1.69
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis (1981) 1.54
Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? Eur J Gastroenterol Hepatol (2001) 1.50
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation (2004) 1.43
Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science (1993) 1.40
Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem (1991) 1.36
Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther (2011) 1.33
Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood (2001) 1.30
Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis (1990) 1.26
Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem (2003) 1.13
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb (1991) 1.09
Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol (1991) 1.07
Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem (2003) 0.99
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis (1993) 0.96
Migration of human vascular smooth muscle cells involves serum-dependent repeated cytosolic calcium transients. J Cell Sci (2000) 0.96
Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells. Hypertension (2002) 0.95
Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem (2001) 0.93
Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol (1998) 0.92
CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation (2000) 0.91
Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem (2008) 0.91
Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells. Am J Physiol Endocrinol Metab (2000) 0.90
Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int (1999) 0.90
TGF-beta 1 causes increased endothelial ICAM-1 expression and lung injury. J Appl Physiol (1985) (1994) 0.90
Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. Hypertension (2002) 0.88
Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. FASEB J (1998) 0.88
The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem (2003) 0.87
Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg (2003) 0.87
Optimal therapy for reduction of lipoprotein(a). J Clin Pharm Ther (2011) 0.87
Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood (1997) 0.86
Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation (1998) 0.85
Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Lipoprotein(a) binding is independent of an arginyl-glycyl-aspartate tripeptide located in apolipoprotein(a). Arterioscler Thromb (1994) 0.85
Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem (1999) 0.85
Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. Atherosclerosis (1997) 0.84
PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro. Atherosclerosis (1996) 0.84
The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin. FASEB J (2008) 0.84
Lipoprotein(a): biology and clinical importance. Clin Biochem Rev (2004) 0.83
Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. J Proteomics (2011) 0.83
Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem (2004) 0.82
Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. Biochem J (2009) 0.82
Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem (1997) 0.82
Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb (1994) 0.80
Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost (2001) 0.80
Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. J Biol Chem (1999) 0.80
The assembly of lipoprotein Lp(a). Eur J Clin Invest (1996) 0.79
Estrogen attenuates vascular remodeling in Lp(a) transgenic mice. Atherosclerosis (2010) 0.79
Effects of lipoprotein(a) and low density lipoprotein on growth of mitogen-stimulated human umbilical vein endothelial cells. Atherosclerosis (1996) 0.78
Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. Arterioscler Thromb Vasc Biol (1996) 0.78
Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis (2000) 0.77
Lipoprotein(a) stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins. Kidney Int (1999) 0.77
Effect of glycated low density lipoprotein on smooth muscle cell proliferation. Int Angiol (1999) 0.77
Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol (1998) 0.77
Lipoprotein(a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways. FEBS Lett (1995) 0.76
Interaction of native and oxidized lipoprotein(a) with human mesangial cells and matrix. Kidney Int (1996) 0.76
An in vitro system for identifying agents capable of changing serum lipoprotein(a) concentration by regulating the transcriptional activity of the apolipoprotein(a) gene promoter. Biochem Biophys Res Commun (1996) 0.76
Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res (2004) 0.76
Apoprotein (A) antagonises THE GPIIB/IIIA receptor on collagen and adp-stimulated human platelets. Front Biosci (2004) 0.76
Stimulatory effects of lipoprotein(a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2. Biochim Biophys Acta (1998) 0.76
Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells. Clin Chim Acta (2000) 0.76
A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility. Circ Res (2006) 2.12
TRPC channel activation by extracellular thioredoxin. Nature (2008) 1.97
Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell (2005) 1.58
Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers. Cardiovasc Res (2010) 1.57
Translocon closure to Ca2+ leak in proliferating vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2009) 1.52
Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation. Circ Res (2011) 1.47
Interactions, functions, and independence of plasma membrane STIM1 and TRPC1 in vascular smooth muscle cells. Circ Res (2008) 1.45
Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction. Circ Res (2010) 1.28
Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J (2005) 1.25
Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nat Protoc (2009) 1.25
Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res (2007) 1.20
Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair (2013) 1.05
Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis (2008) 1.02
Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res (2013) 1.01
Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes (2012) 1.01
Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc Res (2003) 1.00
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol (2007) 1.00
Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol (2009) 1.00
Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J Vasc Surg (2007) 0.99
Nanomolar potency and selectivity of a Ca²⁺ release-activated Ca²⁺ channel inhibitor against store-operated Ca²⁺ entry and migration of vascular smooth muscle cells. Br J Pharmacol (2011) 0.99
Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis (2006) 0.98
Hypoxic modulation of Ca2+ signaling in human venous endothelial cells. Multiple roles for reactive oxygen species. J Biol Chem (2005) 0.97
Human exercise-induced circulating progenitor cell mobilization is nitric oxide-dependent and is blunted in South Asian men. Arterioscler Thromb Vasc Biol (2010) 0.96
Short-term stimulation of calcium-permeable transient receptor potential canonical 5-containing channels by oxidized phospholipids. Arterioscler Thromb Vasc Biol (2010) 0.96
Modulatory effect of interleukin-1α on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase. Matrix Biol (2010) 0.95
Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol (2007) 0.94
Constitutively active TRPC channels of adipocytes confer a mechanism for sensing dietary fatty acids and regulating adiponectin. Circ Res (2012) 0.91
Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin Exp Pharmacol Physiol (2008) 0.91
Inhibition of endothelial cell Ca²⁺ entry and transient receptor potential channels by Sigma-1 receptor ligands. Br J Pharmacol (2013) 0.90
Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am J Physiol Cell Physiol (2009) 0.90
Platelet-derived growth factor maintains stored calcium through a nonclustering Orai1 mechanism but evokes clustering if the endoplasmic reticulum is stressed by store depletion. Circ Res (2012) 0.90
Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation. Int J Biochem Cell Biol (2011) 0.89
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. J Biol Chem (2010) 0.88
Modulation of Ca(2+) signalling in human vascular endothelial cells by hydrogen sulfide. Atherosclerosis (2009) 0.85
Heme oxygenase-1 regulates cell proliferation via carbon monoxide-mediated inhibition of T-type Ca2+ channels. Pflugers Arch (2014) 0.85
Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts. IUBMB Life (2012) 0.84
Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone. Cell Calcium (2011) 0.83
The -1562C/T MMP-9 promoter polymorphism does not predict MMP-9 expression levels or invasive capacity in saphenous vein smooth muscle cells cultured from different patients. Atherosclerosis (2009) 0.83
Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts. J Mol Cell Cardiol (2009) 0.83
Combined effects of interleukin-1α and transforming growth factor-β1 on modulation of human cardiac fibroblast function. Matrix Biol (2013) 0.82
Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. PLoS One (2012) 0.81
Exploring smooth muscle phenotype and function in a bioreactor model of abdominal aortic aneurysm. J Transl Med (2013) 0.81
MMP-3 (5A/6A) polymorphism does not influence human smooth muscle cell invasion. J Surg Res (2011) 0.81
p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts. Biochem Biophys Res Commun (2012) 0.79
Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts. Exp Physiol (2008) 0.79
Divergent effects of 17-β-estradiol on human vascular smooth muscle and endothelial cell function diminishes TNF-α-induced neointima formation. Biochem Biophys Res Commun (2012) 0.78
TRPC1 transcript variants, inefficient nonsense-mediated decay and low up-frameshift-1 in vascular smooth muscle cells. BMC Mol Biol (2011) 0.78
Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms. Int J Biochem Cell Biol (2013) 0.78
Hypoxic remodelling of Ca(2+) signalling in proliferating human arterial smooth muscle. Mol Cell Biochem (2008) 0.77
Interleukin-1 has opposing effects on connective tissue growth factor and tenascin-C expression in human cardiac fibroblasts. Matrix Biol (2013) 0.77
Endothelin-1 is an essential co-factor for beta2-adrenergic receptor-induced proliferation of human cardiac fibroblasts. FEBS Lett (2004) 0.76
Hypoxic regulation of Ca2+ signalling in astrocytes and endothelial cells. Adv Exp Med Biol (2006) 0.75
Restoring Akt1 activity in outgrowth endothelial cells from South Asian men rescues vascular reparative potential. Stem Cells (2014) 0.75
Moderate Versus Heavy Intensity Interval Training For Vascular Health In Post-menopausal Women: A Paradox!: 2862 Board #2 June 3, 1: 00 PM - 3: 00 PM. Med Sci Sports Exerc (2016) 0.75
Progressive Development of Aberrant Smooth Muscle Cell Phenotype in Abdominal Aortic Aneurysm Disease. J Vasc Res (2017) 0.75
T-Type Ca2+ Channel Regulation by CO: A Mechanism for Control of Cell Proliferation. Adv Exp Med Biol (2015) 0.75